|
PolyMedix focuses on developing novel high-value therapeutic drug products for serious, life-threatening acute disorders. We attack these challenges with biomimetics - novel small molecule compounds and polymers which mimic the activity of proteins. These compounds are designed with a proprietary computational technology platform which focuses on a specific field of biology with many potential product opportunities: membrane:protein and protein:protein interactions.
PolyMedix focuses on serious, life threatening, acute disorders which are also significant market opportunities. Using our proprietary computational drug design technology, we have created novel antibiotic compounds and heptagonists. Our lead candidates in each of these programs, i.v. antibiotic candidate PMX-30063 and the anticoagulant antagonist product candidate PMX-60056, are currently in advanced preclinical development. We plan to file Investigational New Drug applications with the U.S. Food and Drug Administration for each during the first quarter of 2008.
PolyMedix is a publicly traded company (OTC BB:PYMX).
August 21, 2008
PolyMedix Initiates Dosing in Phase I Clinical Study of Novel Systemic Antibiotic Compound
PMX-30063 The First and Only Defensin Mimetic Systemic Antibiotic Drug In Human Clinical Trials
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in Canada for its defensin mimetic antibiotic compound, PMX-30063. PolyMedix received a notice of no objection from Health Canada for the Company’s Clinical Trial Application (“CTA”) for PMX-30063 in May 2008. PMX-30063 is the first and only defensin mimetic antibiotic compound to enter human clinical trials for systemic use, and represents an entirely new class of antibiotic drugs.
»read more
|
|
|
August 12, 2008
PolyMedix Has Regulatory Clearance to Initiate Phase I Clinical Study of
Novel Anticoagulant Antagonist Compound
PMX-60056 Heptagonist The Only Reversing Agent for Heparin and Low Molecular
Weight Heparins in Development
PMX-60056 Milestone the Company’s Second Regulatory Clearance in Three Months
Radnor, PA (August 12, 2008) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has clearance to start human clinical trials in the United States with its anticoagulant reversing agent PMX-60056 under the Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents an entirely new class of drug, which PolyMedix calls a heptagonist, and is the only reversing agent for heparin and the Low Molecular Weight Heparins (LMWH) in clinical development. »read more
|
|
